No data to show
XNAS
XLO
Market cap38mUSD
Jul 14, Last price
0.74USD
1D
0.75%
1Q
3.88%
IPO
-95.38%
Name
Xilio Therapeutics Inc
Chart & Performance
P/E
—
P/S
6.04
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.27%
Rev. gr., 5y
%
Revenues
6m
Net income
-58m
L-23.77%
CFO
-18m
L-73.22%
Profile
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 6,344 | |||||
Cost of revenue | 65,989 | 81,033 | 90,996 | |||
Unusual Expense (Income) | ||||||
NOPBT | (59,645) | (81,033) | (90,996) | |||
NOPBT Margin | ||||||
Operating Taxes | (927) | |||||
Tax Rate | ||||||
NOPAT | (59,645) | (81,033) | (90,069) | |||
Net income | (58,241) -23.77% | (76,404) -12.48% | (87,295) 17.49% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,825 | 396 | 16 | |||
BB yield | -13.36% | -2.62% | -0.02% | |||
| Debt | ||||||
Debt current | 1,188 | 3,315 | 7,585 | |||
Long-term debt | 15,096 | 17,379 | 22,461 | |||
Deferred revenue | ||||||
Other long-term liabilities | 19,262 | 1 | 45 | |||
Net debt | (39,007) | (24,010) | (91,901) | |||
| Cash flow | ||||||
Cash from operating activities | (18,378) | (68,620) | (75,723) | |||
CAPEX | (36) | (486) | (1,867) | |||
Cash from investing activities | (36) | (486) | (1,867) | |||
Cash from financing activities | 29,196 | (6,550) | (69) | |||
FCF | (57,503) | (79,394) | (89,312) | |||
| Balance | ||||||
Cash | 55,291 | 44,704 | 120,385 | |||
Long term investments | 1,562 | |||||
Excess cash | 54,974 | 44,704 | 121,947 | |||
Stockholders' equity | (383,748) | (325,509) | (249,105) | |||
Invested Capital | 428,750 | 373,793 | 374,736 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 53,511 | 27,496 | 27,392 | |||
Price | 0.96 73.64% | 0.55 -79.55% | 2.69 -83.19% | |||
Market cap | 51,103 237.92% | 15,123 -79.48% | 73,685 -83.17% | |||
EV | 12,096 | (8,887) | (18,216) | |||
EBITDA | (58,001) | (79,133) | (89,149) | |||
EV/EBITDA | 0.11 | 0.20 | ||||
Interest | 927 | |||||
Interest/NOPBT | ||||||